PTAB Invalidates AbbVie’s Humira Dosing Patent — Again

Drug Industry Daily
A A
The PTO’s Patent Trial and Appeal Board once again ruled that a patent for AbbVie’s Humira was invalid and unpatentable, responding to additional challenges by Boehringer Ingelheim.

To View This Article:

Login

Subscribe To Drug Industry Daily